Answers are grounded in this paper and cite their sources.
Proglumide, a derivative of glutaramic acid which has been used for many years in the treatment of ulcers, was found to inhibit the degradation of the C-terminal octapeptide (CCK-8) of cholecystokinin (CCK) by brain enzymes.Another antagonist of CCK-gastrin receptors, dibutyryl cyclic GMP had no effect.The effect of proglumide was not specific for CCK peptides since the cleavage of the N-terminal tyrosine residue of leucine-enkephalin by brain enzymes was also inhibited.The inhibition did not involve CCK receptors as it was observed for the degradation of CCK-8 by cytosolic synaptosomal enzymes as well as for the cleavage of the peptide by purified synaptic membranes.The inhibition exerted by proglumide on the degradation of unsulfated CCK-8 by synaptic membranes displayed a non-competitive character with an apparent Ki value of 1.3 mM.Two non-competitive K, values (0.6 and 2.0 mM) were found for the inhibition of the cleavage of leu-enkephalin.Proglumide inhibited the degradation of CCK-8 by brain enzymes but was ineifective towards the cleavage of this peptide by pancreatic plasma membranes.Comparison of the structure of proglumide with aminopeptidase inhibitors shows some similarities between these molecules and suggests that this compound might act through the same mechanism on brain CCK-8 and leu-enkephalin degrading aminopeptidases.
No takes yet. Share an insight, caveat, or question.
Deschodt-Lanckman et al. (1982) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: